DSpace@İnönü

Multicenter retrospective analysis regarding the clinical manifestations

Basit öğe kaydını göster

dc.contributor.author Hacioglu, S
dc.contributor.author Bilen, Y
dc.contributor.author Eser, A
dc.contributor.author Sivgin, S
dc.contributor.author Gurkan, E
dc.contributor.author Yildirim, R
dc.contributor.author Aydogdu, I
dc.contributor.author Dogu, MH
dc.contributor.author Yilmaz, M
dc.contributor.author Kayikci, O
dc.contributor.author Tombak, A
dc.contributor.author Kuku, I
dc.contributor.author Celebi, H
dc.contributor.author Akay, MO
dc.contributor.author Esen, R
dc.contributor.author Korkmaz, S
dc.contributor.author Keskin, A
dc.date.accessioned 2022-10-13T11:46:40Z
dc.date.available 2022-10-13T11:46:40Z
dc.date.issued 2015
dc.identifier.uri http://hdl.handle.net/11616/79610
dc.description.abstract In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd.
dc.description.abstract C1 [Hacioglu, Sibel; Dogu, Mehmet Hilmi; Keskin, Ali] Pamukkale Univ, Dept Hematol, TR-20070 Denizli, Turkey.
dc.description.abstract [Bilen, Yusuf; Yildirim, Rahsan] Ataturk Univ, Dept Hematol, Erzurum, Turkey.
dc.description.abstract [Eser, Ali] Marmara Univ, Dept Hematol, Istanbul, Turkey.
dc.description.abstract [Sivgin, Serdar] Erciyes Univ, Dept Hematol, Kayseri, Turkey.
dc.description.abstract [Gurkan, Emel] Cukurova Univ, Dept Hematol, Adana, Turkey.
dc.description.abstract [Aydogdu, Ismet] Celal Bayar Univ, Dept Hematol, Manisa, Turkey.
dc.description.abstract [Yilmaz, Mehmet] Gaziantep Univ, Dept Hematol, Gaziantep, Turkey.
dc.description.abstract [Kayikci, Omur] Ankara Oncol Educ & Res Hosp, Dept Hematol, Ankara, Turkey.
dc.description.abstract [Tombak, Anil] Mersin Univ, Dept Hematol, Mersin, Turkey.
dc.description.abstract [Kuku, Irfan] Inonu Univ, Dept Hematol, Malatya, Turkey.
dc.description.abstract [Celebi, Harika] Diskapi Yildirim Beyazit Educ & Res Hosp, Dept Hematol, Ankara, Turkey.
dc.description.abstract [Akay, Meltem Olga] Osmangazi Univ, Dept Hematol, Eskisehir, Turkey.
dc.description.abstract [Esen, Ramazan] Yuzuncu Yil Univ, Dept Hematol, Van, Turkey.
dc.description.abstract [Korkmaz, Serdal] Cumhuriyet Univ, Dept Hematol, Sivas, Turkey.
dc.source HEMATOLOGICAL ONCOLOGY
dc.title Multicenter retrospective analysis regarding the clinical manifestations
dc.title and treatment results in patients with hairy cell leukemia: twenty-four
dc.title year Turkish experience in cladribine therapy


Bu öğenin dosyaları:

Dosyalar Boyut Biçim Göster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster